A double-blind , randomized , placebo-controlled , multicenter trial of @ months ' duration was conducted in @ subjects , with probable or definite ALS and a slow vital capacity ( SVC ) @ % , receiving @ mg olesoxime daily or matching placebo and @ mg riluzole twice a day in all .